Share this article on:

iPad Extra: Cervical and Prostate Cancer Updates

doi: 10.1097/01.COT.0000436596.55206.60
News

Download the OT iPad app to watch these two video interviews by OT reporter Dan Keller.

Figure. No caption a...
Figure. No caption a...

* Krishnansu Sujata Tewari, MD, Professor of Obstetrics and Gynecology at the University of California, Irvine, elaborates on the data he reported during this year's ASCO Plenary Session, on the benefits of adding bevacizumab to standard chemotherapy for women with advanced stage or recurrent cervical cancer (OT, 7/25/13 issue). The results are “very, very meaningful,” he says, also discussing the implications the findings have on the role of angiogenesis in cervical cancer, as well as what he thinks about novel oral anti-angiogenic agents.

* Nicholas Vogelzang, MD, member of the U.S. Oncology Research Network in Las Vegas, and Medical Director of the Network's Developmental Therapeutics Committee and Co-chair of the Genitourinary Committee, told OT why he's so excited about the encouraging results so far for Xofigo (radium-223 dichloride) for metastatic castration-resistant prostate cancer—which was approved earlier this year (OT 6/10/13 issue). Plus, listen to what he thinks about the drug's potential in other tumor types.

To receive our iPad issues, download the free Oncology Times app from the App Store from http://bit.ly/OT-iPadApp, search in the App Store, or follow the link on oncology-times.com.

Figure. No caption a...
Figure. No caption a...
Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.
Home  Clinical Resource Center
Current Issue       Search OT
Archives Get OT Enews
Blogs Email us!